SeekingAlpha · Aug 7, 2026
Sanofi 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Sanofi in conjunction with their 2026 Q2 earnings call.
SN
NYSE · SNY
Sanofi
Healthcare · Drug Manufacturers - General
$43.78
Down-$0.12 (-0.26%)
Updated Aug 14, 2026, 4:36 PM
SID Score
7.2/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 119.04B
- P/E ratio
- 11.2
- Dividend yield
- 5.05%
- 52-week range
- $40.89 – $52.68
- Volume
- 2.21M
- Avg. volume
- 2.95M
Price performance
SNY price history
1M range · 21 trading sessions · Daily adjusted prices
SNY closed at $43.78 after 21 trading sessions, down 0.97% for the selected period.
- Last close
- $43.78
- Period change
- -0.97%
- Period low
- $42.68
- Period high
- $45.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $43.93 | $44.10 | $43.73 | $43.78 | 2.21M |
| Aug 12, 2026 | $43.49 | $43.78 | $43.34 | $43.71 | 2.93M |
| Aug 11, 2026 | $43.62 | $43.90 | $43.43 | $43.56 | 2.84M |
| Aug 10, 2026 | $43.53 | $43.705 | $43.32 | $43.48 | 3.36M |
| Aug 7, 2026 | $43.57 | $43.865 | $43.34 | $43.46 | 2.77M |
| Aug 6, 2026 | $43.30 | $43.51 | $42.76 | $42.89 | 4.15M |
| Aug 5, 2026 | $43.02 | $43.19 | $42.74 | $42.78 | 2.47M |
| Aug 4, 2026 | $42.77 | $42.90 | $42.54 | $42.68 | 2.28M |
| Aug 3, 2026 | $43.50 | $43.81 | $42.68 | $42.95 | 2.6M |
| Jul 31, 2026 | $43.03 | $43.10 | $42.48 | $43.08 | 2.94M |
| Jul 30, 2026 | $42.04 | $42.93 | $41.42 | $42.89 | 10.2M |
| Jul 29, 2026 | $45.44 | $45.665 | $44.79 | $44.85 | 3.51M |
| Jul 28, 2026 | $44.89 | $45.65 | $44.89 | $45.54 | 2.85M |
| Jul 27, 2026 | $43.73 | $44.495 | $43.51 | $44.00 | 2.96M |
| Jul 24, 2026 | $43.16 | $43.485 | $42.935 | $43.35 | 3.07M |
| Jul 23, 2026 | $43.03 | $43.505 | $42.88 | $43.36 | 1.91M |
| Jul 22, 2026 | $44.70 | $44.72 | $43.79 | $43.79 | 2.83M |
| Jul 21, 2026 | $43.70 | $44.195 | $43.55 | $43.75 | 2.19M |
| Jul 20, 2026 | $44.04 | $44.215 | $43.7634 | $43.98 | 7.1M |
| Jul 17, 2026 | $44.46 | $44.85 | $43.88 | $44.66 | 3.68M |
| Jul 16, 2026 | $43.71 | $44.24 | $43.495 | $44.21 | 2.89M |
Latest SNY news
The latest Smart Investors Daily articles mentioning SNY.
Stock researchCompany · Overview
SNY research
Overview
Company profile and research snapshot.
Company profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $57.02
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Jul 12, 2026 | DAY BY DAY | Sell | — |
| Jul 8, 2026 | BANCO SANTANDER | Outperform | — |
| Jul 1, 2026 | JEFFERIES | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 7, 2026
Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability
SANOFI-ADR (SNY) is a decent value pick: cheap valuation, strong profitability, moderate health/growth, plus a 5.54% dividend yield.
SeekingAlpha · Aug 6, 2026
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
Sanofiâs vaccines segment had a negative 4.7% YoY growth in Q2â26, being dragged down by flu and COVID-19. Learn why SNY stock is a buy.
SeekingAlpha · Jul 30, 2026
Sanofi (SAN:CA) Q2 2026 Earnings Call Transcript
Sanofi (SAN:CA) Q2 2026 Earnings Call July 30, 2026 7:00 AM EDTCompany ParticipantsThomas Larsen - Head of Investor Relations & General MedicinesBelen...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
